News & Views
Telix today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-CDx, (Pixclara®[1], 18F-floretyrosine or 18F-FET), an investigational PET[2]…
Read more
Telix today announces new leadership appointments as part of an internal reorganisation to align its operations across four business units, reflecting its focus as a therapeutics-led radiopharmaceutical company committed to…
Read more
Telix today announces its financial results for the half-year ended 30 June 2024. All figures are in AU$ unless otherwise…
Read more
Telix today advises that it will release its financial results for the half-year ended 30 June 2024 on Thursday 22 August…
Read more
News,
Telix today announces the opening of an expanded access program (EAP) in the United States (U.S.) for TLX101-CDx (Pixclara®1, 18F-floretyrosine or 18F-FET) an investigational positron emission tomography (PET) agent for…
Read more
News,
Modern slavery is a grave human rights violation involving various forms of exploitation, such as forced labour, human trafficking, debt bondage, forced marriage, and child exploitation. It affects millions globally,…
Read more
News,
Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the filing of its New Drug Application (NDA) for TLX007-CDx, a new and proprietary cold…
Read more
Telix is pleased to announce that it has successfully priced A$650 million 2.375 per cent convertible notes due 2029. The convertible notes, also referred to as “convertible bonds” (Convertible Bonds),…
Read more
News,
Telix today launches an offering of A$600 million of convertible notes due 2029 (the Offering). The convertible notes, also referred to as “convertible bonds” (Convertible Bonds), are convertible into fully…
Read more
Telix today provides an update on its revenue and operational performance for the quarter ended 30 June 2024 (Q2…
Read more